\r\n \r\nHi-Tech announced the acquisition of Sinus Buster and Allergy Buster for $1.25 million and an addition $1.25 million that it will deposit in an escrow account. The company also will pay Dynova a royalty on net sales for up to three and a half years or up to $1.75 million. The products, which Hi-Tech will sell through its Health Care Products over-the-counter division, had sales of $3.3 million in 2011. \r\n \r","showSummary":null,"url":"/otc/hi-tech-pharmacal-buys-homeopathic-product-line-dynova-labs","date":"2012-03-08T00:00:00","author":{"email":null,"uname":"Anonymous","firstName":null,"lastName":null,"bio":null,"title":null,"picture":null,"phone":null,"contactForm":null},"byline":"Alaric DeArment","hideByline":null,"digitalEdition":null,"sponsored":false,"sponsorship":{"overrideAds":false},"taggedPro":null,"relatedArticles":[],"teaserImage":null,"heroImageSrcset":null,"hideHero":null,"heroImage":null,"heroCaption":null,"attachedFiles":[],"businessTopic":[],"contentType":[],"company":[],"marketSegment":[],"topics":[{"id":6,"name":"News","url":"/news"},{"id":8,"name":"HEALTH","url":"/health"},{"id":51,"name":"Allergy","url":"/allergy"},{"id":48,"name":"Homeopathy","url":"/homeopathy"}],"contentParagraphs":null,"sections":null};
const country = "US";
const language = null;
const SITE_LANGUAGE = "en";
const siteName = "Drug Store News";
const userRoles = ["anonymous"];
const userUid = 0;
const indexName = "dsnews";
const title = "Hi-Tech Pharmacal buys homeopathic product line from Dynova Labs | Drug Store News";
window.dataLayer = window.dataLayer || [];
const data = {};
data.entityTaxonomy = {};
const contentTypes = [
"article",
"blog",
"bulletin",
"embed_page",
"landing_page",
"event",
"image",
"page",
"product",
"whitepaper",
"video",
"tags",
];
if (
routeInfo &&
"bundle" in routeInfo &&
contentTypes.includes(routeInfo["bundle"])
) {
data.entityBundle = routeInfo.bundle;
data.entityTitle = title || `${routeInfo.title} | ${siteName}`;
data.entityId = routeInfo.id;
data.entityName = routeInfo.author?.uname;
data.entityCreated = routeInfo.created;
data.sponsored = routeInfo.sponsored;
data.sponsor = routeInfo.sponsoringCompany;
data.entityType = "node";
data.entityLangcode = SITE_LANGUAGE;
data.siteName = siteName;
data.drupalLanguage = language;
data.drupalCountry = country;
data.userRoles = userRoles;
data.userUid = userUid;
data.entityTaxonomyKeys = {};
data.entityTaxonomyHierarchies = {};
data.parentNaicsCode = {};
data.isPro = false;
data.algoliaIndexName = indexName;
// Add toxonomy data
const taxonomies = {
businessTopic: "business_topic",
contentType: "content_type",
company: "company",
marketSegment: "market_segment",
};
const getHierarchy = (term, terms = []) => {
terms.push({ id: term.id, name: term.name });
if (term.parentTerm != null) {
getHierarchy(term.parentTerm, terms);
}
return terms;
};
const getTerms = (term, useApiId = false) => {
return { id: useApiId ? term.apiId : term.id, name: term.name };
};
const getKeys = (term) => {
return { id: term.id, name: term.apiId };
};
Object.entries(taxonomies).forEach(([key, item]) => {
terms = routeInfo[key];
if (terms && terms.length > 0) {
data["entityTaxonomy"][item] = terms.map((term) =>
getTerms(term, key === "company")
);
if (key !== "company") {
data["entityTaxonomyKeys"][item] = terms.map(getKeys);
termGroups = [];
terms.forEach((term, termInd) => {
termGroups[termInd] = getHierarchy(term);
});
data["entityTaxonomyHierarchies"][item] = termGroups;
}
}
});
data["entityTaxonomy"]["tags"] = routeInfo["topics"] || [];
// Primary Topic is either the business topic or the top tag.
if (routeInfo["businessTopic"]?.length > 0) {
data["entityPrimaryTopic"] = routeInfo["businessTopic"][0]["name"];
} else {
if (routeInfo["topics"]?.length > 0) {
data["entityPrimaryTopic"] = routeInfo["topics"][0]["name"];
}
}
// Primary and secondary entityNaicsCodes come from the MarketSegment
if (routeInfo.marketSegment?.length > 0) {
data.entityNaicsCode = {};
data["entityNaicsCode"]["id"] = routeInfo["marketSegment"][0]["id"];
data["entityNaicsCode"]["name"] =
routeInfo["marketSegment"][0]["naicsCode"];
if (routeInfo["marketSegment"][0]["parentTerm"] != null) {
data["parentNaicsCode"]["id"] =
routeInfo["marketSegment"][0]["parentTerm"]["id"];
data["parentNaicsCode"]["name"] =
routeInfo["marketSegment"][0]["parentTerm"]["naicsCode"];
}
} else {
data.entityNaicsCode = [];
}
if (routeInfo.taggedPro) {
data.isPro = routeInfo.taggedPro;
}
window.dataLayer.push(data);
} else if (routeInfo && "vid" in routeInfo) {
data.entityBundle = "tags";
data.entityTitle = routeInfo.name;
data.entityId = routeInfo.id;
data.entityName = routeInfo.author?.uname;
data.entityCreated = routeInfo.created;
data.entityType = "taxonomy_term";
data.entityLangcode = SITE_LANGUAGE;
data.siteName = siteName;
data.sponsored = routeInfo.sponsored;
data.sponsor = routeInfo.sponsoringCompany;
data.drupalLanguage = language;
data.drupalCountry = country;
data.userRoles = userRoles;
data.userUid = userUid;
data.algoliaIndexName = indexName;
data["entityTaxonomy"]["tags"] = {
id: routeInfo["id"],
name: routeInfo["name"],
};
window.dataLayer.push(data);
}
})();
Hi-Tech Pharmacal buys homeopathic product line from Dynova Labs | Drug Store News
Hi-Tech Pharmacal buys homeopathic product line from Dynova Labs AMITYVILLE, N.Y. — Drug maker Hi-Tech Pharmacal has bought a line of homeopathic nasal spray products from Dynova Labs, the company said Thursday. Hi-Tech announced the acquisition of Sinus Buster and Allergy Buster for $1.25 million and an addition $1.25 million that it will deposit in an escrow account. The company also will pay Dynova a royalty on net sales for up to three and a half years or up to $1.75 million. The products, which Hi-Tech will sell through its Health Care Products over-the-counter division, had sales of $3.3 million in 2011. "With the addition of these products, we are well-positioned to benefit from the growing trend toward natural, homeopathic treatment options," Hi-Tech president and CEO David Seltzer said. "These brands create a good strategic fit for Health Care Products as we expand our presence in the cough-cold and allergy categories."
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
X
This ad will auto-close in 10 seconds